Universität zu Köln

Langerbeins, Petra, Eichhorst, Barbara and Hallek, Michael (2019). Current treatment strategies for chronic lymphocytic leukemia. Onkologe, 25 (11). S. 1004 - 1009. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Full text not available from this repository.

Abstract

Due to an increasingmolecular understanding of the signal pathways of B-lymphocytes and identification of the kinases involved, many new targeted treatments could be developed. The most and best researched are the kinase inhibitors ibrutinib and idelalisib as well as the BCL2 inhibitor venetoclax. A variety of prognostic and predictive biomarkers have been identified. Currently the selection of first-line treatment is oriented to the TP53 status, immunoglobulin heavy chain gene (IGHV) mutational status and patient fitness. Recent clinical studies underline the effectiveness of the novel substances as first-line treatment and in recurrence situations. Acquired Bruton tyrosine kinase (BTK) resistance, medication-specific side effects and a lack of patient compliance are an increasing clinical problem of the new substances. Additionally, little is known about the long-term toxicity. Therefore, patients should be treated within clinical trials whenever possible. This review article summarizes the most recent developments in the diagnostics and treatment of chronic lymphocytic leukemia (CLL) and the most important aspects for the practice are worked out.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Langerbeins, Petra UNSPECIFIED UNSPECIFIED UNSPECIFIED Eichhorst, Barbara UNSPECIFIED UNSPECIFIED UNSPECIFIED Hallek, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-128646
DOI:	10.1007/s00761-019-00655-y
Journal or Publication Title:	Onkologe
Volume:	25
Number:	11
Page Range:	S. 1004 - 1009
Date:	2019
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1433-0415
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language OPEN-LABEL; RITUXIMAB; CLL; CYCLOPHOSPHAMIDE; FLUDARABINE; IBRUTINIB; CHEMOIMMUNOTHERAPY; OBINUTUZUMAB; VENETOCLAX; PHASE-3 Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/12864